
Subject	Evaluation Advisory Committee Chair Report
---------	--

Category	For Information
----------	-----------------

Section A: Introduction

- This report provides the Board with an overview of the activities of the Evaluation Advisory Committee (EAC) since the Committee Chair last reported to the Board in December 2024.
- The EAC held an in-person meeting on 5-6 March 2025. The next meeting is scheduled for 17-18 September 2025.
- At the 5-6 March 2025 meeting, the EAC provided guidance on: i) progress on the commissioned Gavi 5.1 centralised evaluations, including the Zero-Dose evaluation and the joint COVAX evaluation; ii) EAC engagement in Gavi 5.1 evaluations; iii) the proposed actions in response to the Evaluation Function Review (EFR) recommendations; and iv) the proposed evaluation portfolio to meet Gavi 6.0 evaluative evidence needs, as part of Gavi 6.0 evaluation work planning.
- A dissemination event for Phase 2 of the Zero-Dose evaluation was held on 31 March 2025, bringing together Secretariat colleagues and Alliance partners. Feedback from key Secretariat business owners highlighted the evaluation's design and targeted scope to assess strategic thematic areas in more depth, as an approach that can generate more specific recommendations, thereby increasing utility.
- Emerging lessons from the joint evaluation process with COVAX Pillar Partners for the Joint COVAX evaluation were documented to inform the design, execution, and outcomes of future joint evaluations, and to set a precedent for how Global Health Initiatives (GHIs) can work together to address complex challenges collaboratively and effectively. Following completion of the Evaluation Management Response, a dissemination meeting will be held, likely in September/October 2025.
- The EAC provided further guidance in relation to the recommendations from the Evaluation Function Review and MOPAN assessment, including on developing a vision, strategy and culture for evaluation at Gavi, strengthening PPC engagement, and options for evaluation quality assurance and oversight.
- Work is now underway to design an updated Evaluation Policy and a multi-year evaluation workplan for Gavi 6.0, for consideration, recommendation and eventual approval in Q3-4 2025.
- The Evaluation Strategy will be developed and integrated into the broader Gavi 6.0 Measurement, Evaluation and Learning approach aligned with guidance from the EAC.

- Gavi's Annual Evaluation Report for 2024, published on Gavi's website, provides an overview of recent evaluations and updates on efforts to strengthen Gavi's evaluation function.
- The EAC Chair Report is attached in the form of a presentation as Annex A.
- The EAC Meeting Guidance and EAC Review of Decisions from the 5-6 March 2025 EAC meeting are attached as Annex B and Annex C, respectively.

Annexes

Annex A: EAC Chair Report

Annex B: EAC Meeting Guidance, 5-6 March 2025

Annex C: EAC Review of Decisions, 5-6 March 2025

EVALUATION ADVISORY COMMITTEE CHAIR REPORT

BOARD MEETING

James Hargreaves

24-25 July 2025, Geneva, Switzerland

Overarching issues and guidance

- Gavi 5.1 Evaluation Workplan progress update and use
- Update on the development of the Gavi 6.0 Evaluation Workplan
- Update on measures to strengthen the evaluation function, including actions in response to Evaluation Function Review (EFR) recommendations


Progress update – Gavi 5.1 centralised evaluations

Centralised Evaluation	Progress Update
Evaluation of Gavi's contribution to reaching zero-dose children and missed communities, phase II	<ul style="list-style-type: none"> • Evaluation Management Response (EMR) process near completion. • Summary report, learning briefs and EMR to be published on Gavi's website in early Q2
Joint COVAX Evaluation (COVAX Facility and COVAX AMC and Joint Delivery Efforts)	<ul style="list-style-type: none"> • Final report received in May 2025 • Evaluation Management Response being developed • Publication and dissemination event likely in September
Evaluability assessment of the African Vaccine Manufacturing Accelerator (AVMA)	<ul style="list-style-type: none"> • RFQ launch in Q3 2025
Evaluation of the Big Catch-up	<ul style="list-style-type: none"> • RFP launch in Q4 2025, with final results in mid to late 2026, depending on timing of completion of BCU activities in targeted countries

Dissemination and use of evaluation evidence

- Dissemination event for Zero-Dose Evaluation Phase 2 (March 2025) with high participation from country teams; recommendations considered in Gavi 6.0 design
- Evaluative evidence used to inform APPT discussions on HSIS/Zero-Dose/Partnership (March 2025)
- Country-level learning event for the Joint COVAX Evaluation (April 2025)

Now available on Gavi's website




Annual Evaluation
Report 2024




PEF-TCA in HICs
(decentralised)

Soon to be available on Gavi's website



ZD Phase 2



Joint COVAX
Evaluation

Evaluating the Effective
Use of DHIS2 & Data to
Improve Planning and
Monitoring of
Immunisation, HIV and
AIDS, Malaria and TB
Programmes - Study
with GAVI and Global
Fund

DHIS2 & Data
(decentralised)

Evaluation Function Review

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- Continue developing the evaluation function as a component of the broader MEL system
- Agree that it makes sense to strengthen links with the Programme and Policy Committee (PPC), specifically for recommendation/approval of the Evaluation Policy and workplan with advice from the EAC
- Consider the cost-effectiveness of using an external quality assurance service and develop costed options to inform decisions
- Continue to explore options for a more agile evaluation oversight mechanism for Gavi 6.0
- Clarify the meaning of Evaluation Culture through articulating a clear definition and rationale including how this approach would benefit the evaluation function and the organisation and
- As part of the evaluation strategy development, explore the range of evaluation types that could be used going forward and include these categories in the strategy and planning process

Draft Gavi 6.0 multi-year evaluation workplan*

*The final evaluation workplan will be costed

SG	Evaluation(s): <i>Strategic, operational, programmatic</i>	Year	Partnership
SG1	Vaccine Delivery Platforms: Malaria	TBD	Global Fund
SG2	Big Catch-Up	2026	UNICEF/WHO
	Health Systems and Immunisation Strengthening (HSIS) policy Gavi 6.0 Health Systems Strategy Universal Health Coverage (UHC) / Primary Health Care (PHC) Zero Dose	2028	
	Approach to Fragile and Humanitarian Settings	TBD	
SG3	Gavi 6.0 new Eligibility, Transition and Co-financing (ELTRACO) model <ul style="list-style-type: none"> Economic evaluation of contribution of immunization to countries 	TBD	
SG4	African Vaccine Manufacturing Accelerator (AVMA) evaluability assessment	2026	
Cross-cutting	Mid-Term Evaluation of Gavi 6.0 including (to be confirmed) <ul style="list-style-type: none"> Assessment of progress and readiness Resource allocation and partnerships (incl. Global Health Institutions / progress on Lusaka Agenda) Investments in Innovation Climate emergency Gender mainstreaming 	2028	

- **Feedback from the PPC in May 2025 included:** considerations re: optimal timing for specific evaluations (i.e. vaccine delivery platforms: malaria; MTE, F&H, ELTRACO)
- **Next steps:** consultation with Gavi's Programmatic Leadership Team in August to further develop 6.0 evaluation workplan; revised draft workplan to be shared with EAC in September and PPC in October 2025

Thank you

Gavi 5.1 Revised Centralised Evaluation Workplan

Evaluations	Supplier	Budget	2021	2022	2023	2024	2025
Centralised evaluations of high strategic value to the Board to be commissioned in Gavi 5.1							
Evaluation of Gavi's initial response to COVID-19	Euro Health Group	US\$ 594,000					
COVAX Facility and COVAX AMC formative and baseline study	ITAD	US\$ 1,080,000					
Mid-term evaluation of Gavi's 2021-2025 Strategy	Euro Health Group	US\$ 921,000					
Evaluation of Gavi's contribution to reaching Zero-Dose (ZD) children and missed communities	IPSOS	US\$ 1,558,108			Phase 1	Phase 2	Phase 3 cancelled Zero-Dose on Gavi 6.0 Evaluation Workplan
Evaluation of the operationalisation of Gavi's strategy through Gavi's policies, programmatic guidance, and use of funding levers	Euro Health Group	US\$ 569,000					
COVAX Facility and COVAX AMC, Phase II	Research Triangle Institute	US\$ 1,339,873					
Sustainability/post-transition			Moved to Gavi 6.0 Evaluation Workplan				
African Vaccine Manufacturing Accelerator (AVMA) - Evaluability assessment of endline evaluation	TBD	TBD					
Evaluation of the Big Catch-Up	TBD	TBD					
			Evaluation commissioning period				
			Evaluation implementation and delivery period				

Progress update – decentralised evaluations

Decentralised Evaluation	Team	Timeline
Development, Implementation, Monitoring and Evaluation of a National and/or Subnational Advocacy Strategy for Increased PHC and Immunisation Financing	IF&S	2022–2025
Design, Implementation, Monitoring, Evaluation and Learning of Country Specific DSI (Conditional Cash or Non-Cash Transfers) for Increasing Demand for Vaccinations, Increasing Coverage and Reducing the Number of ZD Children	IF&S	2023–2025
DHI Roadmap Assessments (costed DHI roadmap studies)	HSIS	2023–2025
Evaluation of Gavi's DHI Strategy	HSIS	2023–2025
Evaluation of the Niger Direct Financing Facility	IF&S	2023–2025
Evaluation of the Djibouti Direct Facility Financing (DFF) and Performance-Based Financing (PBF)	IF&S	2023–2025
eLMIS Evaluation in Nigeria	HSIS	2024–2025
Evaluation of the Clinton Health Access Initiative (CHAI) Collaborative Learning Strategic Focus Area (SFA)	IF&S	2024–2025
Evaluation of Gavi's CSO Host Platform (Amref)	PPE	2024–2025
Afghanistan Unconditional Cash Transfers Plus Programme Evaluation	IF&S	2024–2025
Delivery Cascade and the New Role of the Office of the CEO	MEL	2025
Gender Evaluation	HSIS	2025
Evaluation of HFSE-CCEOP Learning Agenda	HSIS	2025-2026
CCEOP Delinking Evaluation	HSIS	2025
Demand Process Evaluation	HSIS	2025

EAC GUIDANCE

EVALUATION ADVISORY COMMITTEE MEETING
5-6 March 2025, Geneva, Switzerland

Item 4 – Gavi 5.1 Evaluation Workplan Update (1 of 3)

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance related to the Zero-Dose Evaluation:

EAC focal members acknowledge that both evaluations were conducted using rigorous methodology. While the first phase focused on the left side of the TOC, the second phase highlighted the country's perspective.

1. With respect to scope and overall next steps to close-out the Zero-Dose evaluation in 2025:
 - Publish Phase 2 Deliverables;
 - Conduct Quality Assessment of Phase 2 Deliverables; and
 - Develop an evaluation management response, given that the scope of Zero-Dose evaluation in Gavi 6.0 could be different.

Item 4 – Gavi 5.1 Evaluation Workplan Update (2 of 3)

2. With respect to next steps for Gavi 6.0 and lessons learned:

Methodological Approach

- Leverage the information collected during Gavi 5.1, including Phase 1, Phase 2, Learning Hub, and other relevant sources;
- Leverage where case studies have been conducted during Zero-Dose Evaluation, and if relevant and possible, take deeper dives with more targeted approaches on the Zero-Dose agenda at the country level; and
- Where possible and relevant, prioritise collecting information from NGOs, as they are key implementers of immunisation programmes in fragile and humanitarian settings.

Comprehensiveness and Efficiency

- Consider implementing the next phase evaluation, either continuing directly with Zero-Dose or integrating that within the HSS evaluation.

Item 4 – Gavi 5.1 Evaluation Workplan Update (3 of 3)

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance related to the COVAX Evaluation:

- Moving forward, joint evaluation processes should be initiated by agency principals; and
- Continue extracting learning from doing joint evaluations, including lighter and more efficient approaches, and tracking their utility.

With respect to the Annual Evaluation Report:

- For CET to revert with an assessment of whether it is worthwhile to continue with a standalone AER format or consider an alternative approach.

Item 5 – Evaluation Function Review: Action Planning

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- Continue developing the evaluation function as a component of the broader MEL system;
- Agree that it makes sense to strengthen links with the Programme and Policy Committee (PPC), specifically for recommendation/approval of the Evaluation Policy and workplan with advice from the EAC;
- Consider the cost-effectiveness of using an external quality assurance service and develop costed options to inform decisions;
- Continue to explore options for a more agile evaluation oversight mechanism for Gavi 6.0;
- Clarify the meaning of Evaluation Culture through articulating a clear definition and rationale including how this approach would benefit the evaluation function and the organisation; and
- As part of the evaluation strategy development, explore the range of evaluation types that could be used going forward and include these categories in the strategy and planning process.

Item 6 – Gavi 6.0 Evaluation Workplan Update

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

With recognition of the evolving scenario, continue to develop the Gavi 6.0 evaluation workplan with attention to:

- Timing and platforms for decision-making by the Board, its Committees, and other stakeholders;
- Improving the proposed “criteria” to guide prioritisation, selection and complementarity of evaluations; and
- Developing a mixed portfolio of evaluation types that addresses a wide range of evidence needs and considers joint evaluations where appropriate.

Cross-cutting guidance

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- Document changing country strategies or actions in the face of potential funding cuts; and
- Prioritise the phased approach to evaluation to ensure agility and utility.

Thank you

REVIEW OF DECISIONS

EVALUATION ADVISORY COMMITTEE MEETING
5-6 March 2025, Geneva, Switzerland

Decision 1: Gavi 5.1 Evaluation Workplan Update

The Gavi Alliance Evaluation Advisory Committee:

Approved the revised multi-year (2021-2025) centralised evaluation workplan attached as Annex A to Doc 04.

Thank you